Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment

Pharmacopsychiatry

Volumn 36, Issue 3, 2003, Pages 105-112

  Loffler W ^a   Kilian, Reinhold ^a   Toumi, M ^b   Angermeyer, M C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; DISEASE SEVERITY; DOCTOR PATIENT RELATION; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; RATING OF MEDICATION INFLUENCES SCALE; RATING SCALE; SCHIZOPHRENIA; SELF REPORT; SEX DIFFERENCE; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AWARENESS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 18544391209     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39985     Document Type: Article

References (48)

1. Agarwal MR, Sharma VK, Kishore Kumar KV, Lowe D. Noncompliance with treatment in patients suffering from schizophrenia: A study to evaluate possible contributing factors. International Journal of Social Psychiatry 1998; 44(2): 92-106
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM IIIR) 3d ed. Washington DC: APA, 1994
3. Angermeyer MC, Löffler W, Müller P, Schulze B, Priebe S. Patients' and relatives' assessment of clozapine treatment. Psychol Med 2001; 31: 509-517
4. Angermeyer MC, Matschinger H. Neuroleptika und Lebensqualität. Psychiatr Prax 2000; 27: 64-68
5. Angermeyer MC, Matschinger H. Public attitude towards psychiatric treatment. Acta Psychiatr Scand 1996; 94: 326-336
6. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 1993; 19: 609-618
7. Awad AG, Hogan TP, Voruganti LNP, Heslegraves RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. International Clinical Pharmacology 1995; 10: 123-132
8. Barnas C, Hummer M, Fleischhacker WW. Compliance Probleme bei der Behandlung schizophrener Patienten. Wiener Medizinische Wochenschrift 1998; 11: 281-283
9. Benkert O, Kepplinger HM, Sobota K. Psychopharmaka im Widerstreit. Berlin: Springer. 1995
10. Bollen KA, Lennox R. Conventional wisdom on measurement: A structural equation perspective. Psychol Bull 1991; 110(2): 305-314
11. Buchanan A. Treatment complicane in schizophrenia. Advances in Psychiatric Treatment 1998; 4: 227-234
12. Cabeza IG, Amador MS, Lopez CA, de Chavez MG. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41: 349-355
13. Chacos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: Areview and meta-analysis of randomized trials. American Journal of Psychiatry 2001; 158: 518-526
14. Chisholm D, Knapp MRJ, Knudson HC, Amaddeo F, Gaite L, vanWijngaarden B. Client Sociodemographic and Service Receipt Inventory - European Version. Br J Psychiatry 2000; 17 (suppl. 39): 28-33
15. Day JC, Kinderman P, Bentall R. A comparison of patients' and prescribers' beliefs about neuroleptic side effects: prevalence, distress and causation. Acta Psychiatr Scand 1998; 97: 93-97
16. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? American Journal of Psychiatry 2002; 159: 103-108
17. Fayers PM, Hand DJ. Factor analysis, causal indicators and quality of life. Qual Life Res 1997; 6(2): 39-150
18. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 23(4): 637-651
19. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981
20. Garcia Cabeza I, Sanz Amador M, Arango Lopez C, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenia patients: clinical implications and related factors. Schizophr Res 2000; 41: 349-355
21. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. International Clinical Psychopharmacology 2002; 17: 65-68
22. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. Journal of Clinical Psychiatry 2002; 63: 49-53
23. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983; 13: 177-183
24. Hornung WP, Feldmann R, Schonauer K, Schafer A, Monking HS, Klingberg S et al. Psychoedukativ-psychotherapeutische Behandlung von schizophrenen Patienten und ihren Bezugspersonen. II. Ergänzende Befunde der 2-Jahres-Katamnese. Nervenarzt 1999; 70(5): 444-449
25. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999; 100(3): 67-175
26. Kampman O, Lethinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A-M. Attitudes toward neuroleptic treatment: Realiability and validity of the Attitudes towards Neuroleptics Treatment (ANT) questionaire. Schizophr Res 2000; 45: 223-234
27. Kilian R, Lindenbach I. Angermeyer MC. "(...) manchmal zweifle ich an mir. wenn es mir nicht gut geht" - Die Wirkung eines ambulanten psychoedukativen Gruppenprogramms aus der subjektiven Perspektive von Patienten mit schizophrenen Erkrankungen. Psychiatr Prax 2001; 28(4): 57-206
28. Kilian R, Roick C, Bernert S, Morry C, Matschinger H, Becker T et al. Die europäische Standardisierung und die deutschsprachige Adaptation von Instrumenten zur Erfassung der Ergebnisse und der Kosten von Versorgungsleistungen für Menschen mit schweren psychischen Erkrankungen. Gesundheitswesen 2001; 63 (Sonderheft 1): 27-31
29. Lilly. Are people with schizophrenia getting the best treatment? Lilly, 2000
30. Linden M, Godemann F, Gaebel W, Köpke W, Müller P, Müller-Spahn F et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. Schizophrenia Bulletin 2001; 27(4): 585-596
31. Lindström E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000; 18(2): 05-124
32. McCallum RC, Brown MW. The use of causal indicators in covariance structure models: Some practical issues. Psychol Bull 1993; 114(3): 533-541
33. Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. British Journal of Clinical Psychology 2000; 39: 287-295
34. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 Suppl 3: 33-138
35. National Institute of Mental Health. 12 - CGI. Clinical global impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU assessment battery; 2. rev. ed Maryland: Chevy Chase, 1970: 12-1-12-6
36. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000; 102: 83-86
37. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Henderson TJ. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry 2000; 61: 382-386
38. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Comprehensive Psychiatry 2000; 41: 446-449
39. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatric Services 1997; 48: 82-85
40. Sellwood W, Tarrier N. Demographic factors associated with extreme noncompliance in schizophrenia. Social Psychiatry and Psychiatric Epidemiology 1994; 29: 172-177
41. Taylor D, Shapland L, Laverick G., Bond J, Munro J. Clozapine - a survey of patient perception. Psychiatr Bull 2000; 24: 450-452
42. Tunnicliffe S, Harrison G, Standen PJ. Factors affecting compliance with depot injection treatment in the community. Social Psychiatry and Psychiatric Epidemiology 1992; 27: 230-233
43. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry 2001; 62: 545-551
44. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Arch Gen Psychiatr 1978; 35: 477-480
45. Ventura J, Green MF, Shaner A, Lieberman R.P. Training and quality assurance with the brief psychiatric rating scale: "The Drift Busters". Intern Meth Psychiatr Res 1993; 3: 221-244
46. Wahlbeck K, Tuunainen A, Ahokas A. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 2001; 155: 230-233
47. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz LM et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 20(2): 297-310
48. Wolfson P.W., Paton C. Clozapine audit: What do patients and relatives think? J Ment Hlth 1996; 5(3): 267-273